A Novel Truncated CHAP Modular Endolysin, CHAPSAP26-161, That Lyses Staphylococcus aureus, Acinetobacter baumannii, and Clostridioides difficile, and Exhibits Therapeutic Effects in a Mouse Model of A. baumannii Infection.
Yoon-Jung Choi, Shukho Kim, Ram Hari Dahal, Jungmin Kim
{"title":"A Novel Truncated CHAP Modular Endolysin, CHAP<sup>SAP26</sup>-161, That Lyses <i>Staphylococcus aureus</i>, <i>Acinetobacter baumannii</i>, and <i>Clostridioides difficile</i>, and Exhibits Therapeutic Effects in a Mouse Model of <i>A. baumannii</i> Infection.","authors":"Yoon-Jung Choi, Shukho Kim, Ram Hari Dahal, Jungmin Kim","doi":"10.4014/jmb.2402.02042","DOIUrl":null,"url":null,"abstract":"<p><p>Development of novel antibacterial agents is imperative due to the increasing threat of antibiotic-resistant pathogens. This study aimed to develop the enhanced antibacterial activity and in-vivo efficacy of a novel truncated endolysin, CHAP<sup>SAP26</sup>-161, derived from the endolysin LysSAP26, against multidrug-resistant bacteria. CHAP<sup>SAP26</sup>-161 exhibited higher protein purification efficiency in E. coli and antibacterial activity than LysSAP26. Moreover, CHAP<sup>SAP26</sup>-161 showed the higher lytic activity against <i>A. baumannii</i> with minimal bactericidal concentrations (MBCs) of 5-10 μg/ml, followed by <i>Staphylococcus aureus</i> with MBCs of 10-25 μg/ml. Interestingly, CHAP<sup>SAP26</sup>-161 could lyse anaerobic bacteria, such as <i>Clostridioides difficile</i>, with MBCs of 25-50 μg/ml. At pH 4-8 and temperatures of 4°C-45°C, CHAP<sup>SAP26</sup>-161 maintained antibacterial activity without remarkable difference. The lytic activity of CHAP<sup>SAP26</sup>-161 was increased with Zn<sup>2+</sup>. In vivo tests demonstrated the therapeutic effects of CHAP<sup>SAP26</sup>-161 in murine systemic <i>A. baumannii</i> infection model. In conclusion, CHAP<sup>SAP26</sup>-161, a truncated endolysin that retains only the CHAP domain from LysSAP26, demonstrated enhanced protein purification efficiency and antibacterial activity compared to LysSAP26. It further displayed broad-spectrum antibacterial effects against <i>S. aureus</i>, <i>A. baumannii</i>, and <i>C. difficile</i>. Our in vitro and in-vivo results of CHAP<sup>SAP26</sup>-161 highlights its promise as an innovative therapeutic option against those bacteria with multiple antibiotic resistance.</p>","PeriodicalId":16481,"journal":{"name":"Journal of microbiology and biotechnology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380504/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of microbiology and biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.4014/jmb.2402.02042","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Development of novel antibacterial agents is imperative due to the increasing threat of antibiotic-resistant pathogens. This study aimed to develop the enhanced antibacterial activity and in-vivo efficacy of a novel truncated endolysin, CHAPSAP26-161, derived from the endolysin LysSAP26, against multidrug-resistant bacteria. CHAPSAP26-161 exhibited higher protein purification efficiency in E. coli and antibacterial activity than LysSAP26. Moreover, CHAPSAP26-161 showed the higher lytic activity against A. baumannii with minimal bactericidal concentrations (MBCs) of 5-10 μg/ml, followed by Staphylococcus aureus with MBCs of 10-25 μg/ml. Interestingly, CHAPSAP26-161 could lyse anaerobic bacteria, such as Clostridioides difficile, with MBCs of 25-50 μg/ml. At pH 4-8 and temperatures of 4°C-45°C, CHAPSAP26-161 maintained antibacterial activity without remarkable difference. The lytic activity of CHAPSAP26-161 was increased with Zn2+. In vivo tests demonstrated the therapeutic effects of CHAPSAP26-161 in murine systemic A. baumannii infection model. In conclusion, CHAPSAP26-161, a truncated endolysin that retains only the CHAP domain from LysSAP26, demonstrated enhanced protein purification efficiency and antibacterial activity compared to LysSAP26. It further displayed broad-spectrum antibacterial effects against S. aureus, A. baumannii, and C. difficile. Our in vitro and in-vivo results of CHAPSAP26-161 highlights its promise as an innovative therapeutic option against those bacteria with multiple antibiotic resistance.
期刊介绍:
The Journal of Microbiology and Biotechnology (JMB) is a monthly international journal devoted to the advancement and dissemination of scientific knowledge pertaining to microbiology, biotechnology, and related academic disciplines. It covers various scientific and technological aspects of Molecular and Cellular Microbiology, Environmental Microbiology and Biotechnology, Food Biotechnology, and Biotechnology and Bioengineering (subcategories are listed below). Launched in March 1991, the JMB is published by the Korean Society for Microbiology and Biotechnology (KMB) and distributed worldwide.